| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 115.34B | 115.59B | 108.28B | 103.61B | 93.74B | 81.37B |
| Gross Profit | 32.97B | 32.79B | 31.03B | 29.42B | 27.66B | 24.85B |
| EBITDA | 9.89B | 8.25B | 13.15B | 13.07B | 8.40B | 11.20B |
| Net Income | 2.22B | 1.50B | 6.18B | 5.72B | 1.21B | 3.94B |
Balance Sheet | ||||||
| Total Assets | 116.88B | 120.69B | 125.62B | 118.97B | 116.38B | 116.28B |
| Cash, Cash Equivalents and Short-Term Investments | 15.34B | 17.71B | 17.93B | 17.96B | 19.57B | 19.30B |
| Total Debt | 2.13B | 7.14B | 7.59B | 11.57B | 13.83B | 20.00B |
| Total Liabilities | 33.83B | 38.19B | 40.11B | 40.96B | 43.95B | 45.52B |
| Stockholders Equity | 82.81B | 82.13B | 85.16B | 77.66B | 72.13B | 70.49B |
Cash Flow | ||||||
| Free Cash Flow | 8.57B | 6.50B | 9.69B | 3.99B | 5.99B | 6.27B |
| Operating Cash Flow | 12.88B | 10.76B | 14.06B | 7.71B | 9.59B | 10.17B |
| Investing Cash Flow | -3.30B | -4.19B | -4.74B | -3.98B | -534.00M | -2.77B |
| Financing Cash Flow | -9.48B | -6.91B | -8.96B | -6.43B | -9.94B | -3.63B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥102.61B | 15.69 | ― | 4.85% | 5.22% | -28.13% | |
75 Outperform | ¥121.53B | 14.42 | ― | 2.56% | -0.98% | -18.48% | |
74 Outperform | ¥112.20B | 10.47 | ― | 2.49% | 12.64% | 34.19% | |
73 Outperform | ¥100.68B | 13.39 | ― | 2.89% | 15.99% | 32.43% | |
69 Neutral | ¥136.61B | 24.01 | ― | 3.82% | >-0.01% | -26.82% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | ¥82.97B | 27.12 | ― | 3.95% | 3.68% | -46.19% |
Bando Chemical Industries, Ltd. announced the acquisition of 109,200 of its own shares between September 1 and September 30, 2025, at a cost of 223,709,089 yen. This is part of a larger plan approved in May 2025 to acquire up to 1,800,000 shares, reflecting the company’s strategy to optimize capital structure and potentially enhance shareholder value.
The most recent analyst rating on (JP:5195) stock is a Hold with a Yen2096.00 price target. To see the full list of analyst forecasts on Bando Chemical Industries Ltd. stock, see the JP:5195 Stock Forecast page.
Bando Chemical Industries Ltd. announced the acquisition of its own shares, acquiring 191,400 shares at a cost of 368,523,992 yen during August 2025. This move is part of a larger plan approved by the Board of Directors to acquire up to 1.8 million shares by April 2026, reflecting a strategic effort to enhance shareholder value and optimize capital structure.
The most recent analyst rating on (JP:5195) stock is a Hold with a Yen2096.00 price target. To see the full list of analyst forecasts on Bando Chemical Industries Ltd. stock, see the JP:5195 Stock Forecast page.
Bando Chemical Industries reported a slight decline in revenue for the three months ended June 30, 2025, with a 0.9% decrease compared to the previous year. Despite this, the company saw significant increases in operating profit and profit before tax, indicating improved operational efficiency. The company’s financial position remains strong, with a high ratio of equity attributable to owners of the parent to total assets. The forecast for the fiscal year ending March 31, 2026, anticipates a slight decrease in revenue but substantial growth in operating profit and profit attributable to owners of the parent, suggesting a positive outlook for stakeholders.
Bando Chemical Industries, Ltd. has announced the acquisition of 172,600 of its own shares, costing approximately 299 million yen, during July 2025. This move is part of a broader plan approved by the Board of Directors to acquire up to 1.8 million shares by April 2026, with a maximum budget of 2 billion yen, indicating a strategic effort to consolidate ownership and potentially enhance shareholder value.